Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
11a
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/19/2020
Galidesivir
Potential treatment - theoretical effect Experimental Antiviral Mar/25/2021
Ebselen
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
N3
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/11/2020
FN3A
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
Dactolisib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/17/2021
Ochromycinone
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
N-[(2S)-1-[[(1S,2S)-1-(1,3-Benzothiazol-2-yl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
S2N12
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Cov2-16
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
Darapladib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Tixagevimab
Emergency use authorization Experimental Antiviral Jun/18/2022
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
8-{3-hydroxy-4-[(7-hydroxynaphthalen-2-yl)oxy]phenoxy}-1,4-benzodioxin-5-ol
Potential treatment - theoretical effect Experimental Antiviral Apr/25/2021
Litronesib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
CoV2-09
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
S2X324
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Pyridone 6
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
Flumatinib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
CoV2-26
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021